302 related articles for article (PubMed ID: 31768017)
21. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
23. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
24. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
[TBL] [Abstract][Full Text] [Related]
25. JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
Lynch JR; Salik B; Connerty P; Vick B; Leung H; Pijning A; Jeremias I; Spiekermann K; Trahair T; Liu T; Haber M; Norris MD; Woo AJ; Hogg P; Wang J; Wang JY
Leukemia; 2019 Jun; 33(6):1400-1410. PubMed ID: 30622285
[TBL] [Abstract][Full Text] [Related]
26. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
[TBL] [Abstract][Full Text] [Related]
28. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
[TBL] [Abstract][Full Text] [Related]
29. The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia.
Dancik GM; Varisli L; Vlahopoulos SA
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298333
[TBL] [Abstract][Full Text] [Related]
30. Photodynamic therapy with 5-aminolevulinic acid (ALA) impairs tumor initiating and chemo-resistance property in head and neck cancer-derived cancer stem cells.
Yu CH; Yu CC
PLoS One; 2014; 9(1):e87129. PubMed ID: 24475244
[TBL] [Abstract][Full Text] [Related]
31. ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with β-catenin.
Wang W; He S; Zhang R; Peng J; Guo D; Zhang J; Xiang B; Li L
Biomed Pharmacother; 2020 May; 125():109940. PubMed ID: 32044720
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.
Velu CS; Chaubey A; Phelan JD; Horman SR; Wunderlich M; Guzman ML; Jegga AG; Zeleznik-Le NJ; Chen J; Mulloy JC; Cancelas JA; Jordan CT; Aronow BJ; Marcucci G; Bhat B; Gebelein B; Grimes HL
J Clin Invest; 2014 Jan; 124(1):222-36. PubMed ID: 24334453
[TBL] [Abstract][Full Text] [Related]
33. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
Simões BM; O'Brien CS; Eyre R; Silva A; Yu L; Sarmiento-Castro A; Alférez DG; Spence K; Santiago-Gómez A; Chemi F; Acar A; Gandhi A; Howell A; Brennan K; Rydén L; Catalano S; Andó S; Gee J; Ucar A; Sims AH; Marangoni E; Farnie G; Landberg G; Howell SJ; Clarke RB
Cell Rep; 2015 Sep; 12(12):1968-77. PubMed ID: 26387946
[TBL] [Abstract][Full Text] [Related]
34. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal.
Heuser M; Sly LM; Argiropoulos B; Kuchenbauer F; Lai C; Weng A; Leung M; Lin G; Brookes C; Fung S; Valk PJ; Delwel R; Löwenberg B; Krystal G; Humphries RK
Blood; 2009 Nov; 114(19):3983-93. PubMed ID: 19667399
[TBL] [Abstract][Full Text] [Related]
35. TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways.
Pulikkottil AJ; Bamezai S; Ammer T; Mohr F; Feder K; Vegi NM; Mandal T; Kohlhofer U; Quintanilla-Martinez L; Sinha A; Buske C; Rawat VPS
Leukemia; 2022 Feb; 36(2):416-425. PubMed ID: 34462525
[TBL] [Abstract][Full Text] [Related]
36. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
[TBL] [Abstract][Full Text] [Related]
37. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
39. A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.
Griessinger E; Anjos-Afonso F; Pizzitola I; Rouault-Pierre K; Vargaftig J; Taussig D; Gribben J; Lassailly F; Bonnet D
Stem Cells Transl Med; 2014 Apr; 3(4):520-9. PubMed ID: 24493855
[TBL] [Abstract][Full Text] [Related]
40. BTYNB, an inhibitor of RNA binding protein IGF2BP1 reduces proliferation and induces differentiation of leukemic cancer cells.
Jamal A; Hassan Dalhat M; Jahan S; Choudhry H; Imran Khan M
Saudi J Biol Sci; 2023 Mar; 30(3):103569. PubMed ID: 36816728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
